Evidence map›Paper›PMID 36454924›Full record

ArticlePloS one2022

Development of a multi-year white-nose syndrome mitigation strategy using antifungal volatile organic compounds.

Kyle T Gabriel, Ashley G McDonald, Kelly E Lutsch, Peter E Pattavina, Katrina M Morris, Emily A Ferrall, Sidney A Crow, Christopher T Cornelison

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Microbiota diversity and anti-Applied and environmental microbiology · 2024
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Kyle T GabrielDepartment of Molecular and Cellular Biology, Kennesaw State University, Kennesaw, Georgia, United States of America.ORCID 0000-0003-2166-8774
Ashley G McDonaldDepartment of Molecular and Cellular Biology, Kennesaw State University, Kennesaw, Georgia, United States of America.ORCID 0000-0001-9075-5893
Kelly E LutschDepartment of Molecular and Cellular Biology, Kennesaw State University, Kennesaw, Georgia, United States of America.
Peter E PattavinaUnited States Fish and Wildlife Service, Ecological Services, Athens, Georgia, United States of America.
Katrina M MorrisGeorgia Department of Natural Resources, Wildlife Resources Division, Wildlife Conservation Section, Social Circle, Georgia, United States of America.
Emily A FerrallGeorgia Department of Natural Resources, Wildlife Resources Division, Wildlife Conservation Section, Social Circle, Georgia, United States of America.
Sidney A CrowDepartment of Biology, Georgia State University, Atlanta, Georgia, United States of America.
Christopher T CornelisonDepartment of Molecular and Cellular Biology, Kennesaw State University, Kennesaw, Georgia, United States of America.
Kennesaw State University · USGeorgia Department of Natural Resources · USGeorgia State University · USUnited States Fish and Wildlife Service · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pseudogymnoascus destructans is a fungal pathogen responsible for a deadly disease among North American bats known as white-nose syndrome (WNS). Since detection of WNS in the United States in 2006, its rapid spread and high mortality has challenged development of treatment and prevention methods, a significant objective for wildlife management agencies. In an effort to mitigate precipitous declines in bat populations due to WNS, we have developed and implemented a multi-year mitigation strategy at Black Diamond Tunnel (BDT), Georgia, singly known as one of the most substantial winter colony sites for tricolored bats (Perimyotis subflavus), with pre-WNS abundance exceeding 5000 individuals. Our mitigation approach involved in situ treatment of bats at the colony level through aerosol distribution of antifungal volatile organic compounds (VOCs) that demonstrated an in vitro ability to inhibit P. destructans conidia germination and mycelial growth through contact-independent exposure. The VOCs evaluated have been identified from microbes inhabiting naturally-occurring fungistatic soils and endophytic fungi. These VOCs are of low toxicity to mammals and have been observed to elicit antagonism of P. destructans at low gaseous concentrations. Cumulatively, our observations resolved no detrimental impact on bat behavior or health, yet indicated a potential for attenuation of WNS related declines at BDT and demonstrated the feasibility of this novel disease management approach.

Indexed as

ChiropteraVolatile Organic CompoundsAnimalsAntifungal AgentsAzo CompoundsDioxinsHumansNoseSyndromeTryptaminesAntifungal AgentsAzo CompoundsDioxinseriochrome black AN-((2,3-dihydro-1,4-benzodioxin-2-yl)methyl)-5-methoxy-1H-indole-3-ethanamineTryptaminesVolatile Organic Compounds

Identifiers

PMID36454924
PMCPMC9714803
OpenAlexW4310522154

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.